ALSUntangled #74: Withania Somnifera (Ashwagandha)

Sartaj Jhooty,Paul Barkhaus,Andrew Brown,Javier Mascias Cadavid,Gregory T. Carter,Jesse Crayle,Terry Heiman-Patterson,Xiaoyan Li,Elise Mallon,Christopher Mcdermott,Tasnim Mushannen,Gary Pattee,Dylan Ratner,Paul Wicks,Martina Wiedau,Richard Bedlack
DOI: https://doi.org/10.1080/21678421.2024.2311721
2024-02-08
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Abstract:ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS) who ask about them. Here, we review withania somnifera (WS) commonly known as ashwagandha or winter cherry. WS has plausible mechanisms for slowing ALS progression because of its effects on inflammation, oxidative stress, autophagy, mitochondrial function, and apoptosis. Preclinical trials demonstrate that WS slows disease progression in multiple different animal models of ALS. Of the five individuals we found who described using WS for their ALS, two individuals reported moderate benefit while none reported experiencing any significant side effects. There is currently one clinical trial using WS to treat PALS; the results are not yet published. There are no serious side effects associated with WS and the associated cost of this treatment is low. Based on the above information, WS appears to us to be a good candidate for future ALS trials.
clinical neurology
What problem does this paper attempt to address?